|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
SG194510A1
(en)
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
DK2794658T3
(en)
*
|
2011-12-19 |
2017-06-19 |
Synimmune Gmbh |
BISPECIFIC ANTIBODY MOLECULE
|
|
CA2891764A1
(en)
*
|
2012-11-19 |
2014-05-22 |
Baliopharm Ag |
Recombinant bispecific antibody binding to cd20 and cd95
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2911514A1
(en)
|
2013-05-06 |
2014-11-13 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
CN106459990B
(zh)
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
KR20160125965A
(ko)
*
|
2014-02-28 |
2016-11-01 |
아스테라스 세이야쿠 가부시키가이샤 |
신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
|
|
SG11201606791YA
(en)
*
|
2014-03-03 |
2016-09-29 |
Academia Sinica |
Bi-specific antibodies and uses thereof
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
US10519234B2
(en)
*
|
2014-06-27 |
2019-12-31 |
Innate Pharma |
NKp46 binding proteins
|
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
WO2016011571A1
(en)
*
|
2014-07-21 |
2016-01-28 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
CN104558192B
(zh)
*
|
2015-01-21 |
2018-12-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体her2xcd3的构建及应用
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll－1嵌合抗原受体的癌症治疗
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
JP6796059B2
(ja)
|
2014-09-12 |
2020-12-02 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｗｎｔシグナリングアゴニスト分子
|
|
IL278574B2
(en)
|
2014-11-12 |
2024-11-01 |
Seagen Inc |
Glycan-interacting compounds and methods of use
|
|
JP6779873B2
(ja)
*
|
2014-11-12 |
2020-11-04 |
メモリアル スローン ケタリング キャンサー センター |
抗コンドロイチン硫酸プロテオグリカン４抗体およびその使用
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
US11253546B2
(en)
|
2014-12-15 |
2022-02-22 |
The Regents Of The University Of California |
Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
|
|
CN106659779B
(zh)
*
|
2014-12-22 |
2021-05-18 |
西雅图免疫公司 |
双特异性四价抗体及其制造和使用方法
|
|
CN105821029A
(zh)
*
|
2015-01-04 |
2016-08-03 |
彭霞 |
异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
|
|
CN104774268B
(zh)
*
|
2015-01-21 |
2018-09-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体egfr×cd3的构建及应用
|
|
CN104788567B
(zh)
*
|
2015-01-21 |
2019-03-26 |
武汉友芝友生物制药有限公司 |
一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用
|
|
CN104592391B
(zh)
*
|
2015-01-21 |
2020-08-21 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体EpCAM×CD3的构建及应用
|
|
CN104628866B
(zh)
*
|
2015-01-21 |
2018-03-27 |
中国药科大学 |
一种靶向vegfr2的抗体融合蛋白的制备及其用途
|
|
CN104558193B
(zh)
*
|
2015-01-21 |
2019-01-11 |
武汉友芝友生物制药有限公司 |
一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用
|
|
CN104592395B
(zh)
*
|
2015-01-27 |
2017-11-14 |
中国药科大学 |
Vegfr2单链抗体与mica融合蛋白的制备方法及用途
|
|
WO2016207867A1
(en)
|
2015-02-25 |
2016-12-29 |
Université Du Luxembourg |
Nat8l and n-acetylaspartate in cancer
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
JP7340221B2
(ja)
|
2015-05-01 |
2023-09-07 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア |
グリカン依存性免疫療法分子
|
|
TWI716405B
(zh)
*
|
2015-05-07 |
2021-01-21 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
|
US20180194861A1
(en)
*
|
2015-07-10 |
2018-07-12 |
Abbvie Inc. |
IgM- or IgE-Modified Binding Proteins and Uses Thereof
|
|
TWI829617B
(zh)
*
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
*
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
BR112017026543A2
(pt)
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
plataforma de anticorpo multiespecífico e métodos relacionados
|
|
LU92815B1
(en)
|
2015-09-04 |
2017-03-20 |
Univ Luxembourg |
Inhibitor of dj-1 for therapy
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180053674A
(ko)
*
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
CR20180171A
(es)
*
|
2015-10-07 |
2018-05-03 |
Hoffmann La Roche |
Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
|
|
CN107531793B
(zh)
|
2015-10-13 |
2022-01-11 |
优瑞科生物技术公司 |
对人类cd19具有专一性的抗体药剂和其用途
|
|
EP3370771A4
(en)
|
2015-11-03 |
2019-06-19 |
Ambrx, Inc. |
ANTI-CD3-FOLAT-CONJUGATES AND ITS USES
|
|
WO2017083582A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
US20180327499A1
(en)
*
|
2015-11-13 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
|
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
|
EP3192810A1
(en)
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
EP3430050A1
(en)
*
|
2016-03-15 |
2019-01-23 |
Cancer Research Technology Limited |
Antibodies and related molecules and uses thereof
|
|
US11291721B2
(en)
*
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
US11104738B2
(en)
|
2016-04-04 |
2021-08-31 |
Hemogenyx Pharmaceuticals Llc |
Monoclonal antibodies to human FLT3/FLK2 receptor protein
|
|
JP2019513836A
(ja)
|
2016-04-04 |
2019-05-30 |
ヘモジェニックス リミテッド ライアビリティ カンパニー |
二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
CN107556388A
(zh)
*
|
2016-06-30 |
2018-01-09 |
中国科学院深圳先进技术研究院 |
抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
|
|
GB201611530D0
(en)
*
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
CN106632681B
(zh)
*
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
EP3526257A2
(en)
*
|
2016-10-14 |
2019-08-21 |
Dana-Farber Cancer Institute, Inc. |
Modular tetravalent bispecific antibody platform
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
JP7350313B2
(ja)
|
2016-12-16 |
2023-09-26 |
ブルーフィン バイオメディシン， インコーポレイテッド |
抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
|
|
CA3047070A1
(en)
*
|
2017-01-03 |
2018-07-12 |
F.Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
CN110944651A
(zh)
*
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
US20200095327A1
(en)
*
|
2017-02-08 |
2020-03-26 |
Dragonfly Therapeutics, Inc. |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
KR20240044544A
(ko)
|
2017-03-03 |
2024-04-04 |
씨젠 인크. |
글리칸-상호작용 화합물 및 사용 방법
|
|
CN113336849A
(zh)
*
|
2017-03-28 |
2021-09-03 |
礼进生物医药科技（上海）有限公司 |
用于增强肿瘤微环境中免疫应答的治疗剂和方法
|
|
JP7205995B2
(ja)
*
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
|
|
CN110573528B
(zh)
*
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
|
EP3635000A4
(en)
*
|
2017-05-16 |
2021-04-14 |
The Johns Hopkins University |
Manabodies and methods of using
|
|
WO2018217947A1
(en)
*
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
|
CN108948195B
(zh)
*
|
2017-05-23 |
2022-05-31 |
胡毅 |
一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
|
|
MY201327A
(en)
*
|
2017-06-02 |
2024-02-16 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
|
EP3630841A1
(en)
*
|
2017-06-02 |
2020-04-08 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
|
WO2019023097A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Smet Pharmaceutical Inc |
ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
|
|
KR20200033302A
(ko)
*
|
2017-07-31 |
2020-03-27 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 flt3에 결합하는 단백질
|
|
JP2020533002A
(ja)
*
|
2017-09-13 |
2020-11-19 |
ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
メラニン抗体及びその使用
|
|
JP7036909B2
(ja)
*
|
2017-10-10 |
2022-03-15 |
サノフイ |
抗ｃｄ３８抗体および使用方法
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
IL321773A
(en)
|
2017-10-14 |
2025-08-01 |
Cytomx Therapeutics Inc |
Activatable antibodies and methods for preparing them
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
US11746150B2
(en)
|
2017-12-19 |
2023-09-05 |
Surrozen Operating, Inc. |
Anti-LRP5/6 antibodies and methods of use
|
|
CA3085596A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-frizzled antibodies and methods of use
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CA3090236A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
KR102832460B1
(ko)
|
2018-02-20 |
2025-07-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
|
|
CA3090464A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Affimed Gmbh |
Bispecific egfr/cd16 antigen-binding protein
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
BR112020023299A2
(pt)
*
|
2018-05-16 |
2021-02-02 |
Dragonfly Therapeutics, Inc. |
proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos
|
|
CA3100349A1
(en)
*
|
2018-05-17 |
2019-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor inhibition by phosphatase recruitment
|
|
EA202091977A1
(ru)
*
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
KR20210009421A
(ko)
*
|
2018-06-14 |
2021-01-26 |
바이오아트라, 엘엘씨 |
다중 특이적 항체 구조체
|
|
EP3810642A1
(en)
|
2018-06-21 |
2021-04-28 |
Technische Universität München |
Hepatitis b and/or hepatitis d-permissive cells and animals
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
KR102834084B1
(ko)
*
|
2018-07-17 |
2025-07-14 |
트리움비라 이뮤놀로직스 유에스에이, 인크. |
다양한 구조 최적화를 갖는 t 세포-항원 커플러
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
MA53293A
(fr)
|
2018-08-08 |
2021-11-17 |
Dragonfly Therapeutics Inc |
Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MX2021001527A
(es)
|
2018-08-08 |
2021-06-15 |
Dragonfly Therapeutics Inc |
Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3623383A1
(en)
|
2018-09-11 |
2020-03-18 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Improved bispecific flt3xcd3 antigen binding proteins
|
|
JP7495409B2
(ja)
*
|
2018-09-11 |
2024-06-04 |
ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ |
改善された抗ｆｌｔ３抗原結合タンパク質
|
|
JP7575100B2
(ja)
*
|
2018-11-13 |
2024-10-29 |
ジェイエヌ バイオサイエンシーズ エルエルシー |
免疫細胞活性化のための二重特異性抗体
|
|
WO2020127618A1
(en)
*
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
WO2020132810A1
(en)
*
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
EP3941941A1
(en)
|
2019-03-22 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Egfr x cd28 multispecific antibodies
|
|
JP2022531444A
(ja)
*
|
2019-05-06 |
2022-07-06 |
ブラウン ユニバーシティ |
腫瘍細胞に対するｔ細胞を介した細胞傷害効果が増大したｃｈｉ３ｌ１およびｐｄ１に対する二重特異性抗体
|
|
KR20220017892A
(ko)
*
|
2019-05-08 |
2022-02-14 |
얀센 바이오테크 인코포레이티드 |
T세포 매개 면역의 조절을 위한 물질 및 방법
|
|
CN115298217A
(zh)
*
|
2019-10-15 |
2022-11-04 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16及flt3的蛋白质
|
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CN113088495B
(zh)
*
|
2020-01-09 |
2024-08-16 |
苏州方德门达新药开发有限公司 |
工程改造的t细胞、其制备及应用
|
|
IL294302A
(en)
*
|
2020-01-09 |
2022-08-01 |
Biomunex Pharmaceuticals |
Multispecific antibodies that bind both mait and tumor cells
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
IL296358A
(en)
*
|
2020-03-13 |
2022-11-01 |
Janssen Biotech Inc |
Materials and methods for modulating delta chain mediated immunity
|
|
EP4132582A4
(en)
*
|
2020-04-10 |
2024-07-24 |
The Board of Trustees of the Leland Stanford Junior University |
TARGETED REDUCTION OF ACTIVATED IMMUNE CELLS
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
TW202216769A
(zh)
*
|
2020-06-23 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ｈｅｒ２的激動性ｃｄ２８抗原結合分子
|
|
KR102607909B1
(ko)
*
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
TW202233674A
(zh)
|
2020-10-28 |
2022-09-01 |
美商健生生物科技公司 |
用於調節δγ鏈介導之免疫的組成物及方法
|
|
AU2021368272A1
(en)
*
|
2020-11-02 |
2023-06-08 |
Attralus, Inc. |
Sap fc fusion proteins and methods of use
|
|
JP2023547507A
(ja)
|
2020-11-03 |
2023-11-10 |
ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ |
標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
PE20231503A1
(es)
|
2021-02-26 |
2023-09-26 |
Bayer Ag |
INHIBIDORES DE IL-11 O IL-11Ra PARA USO EN EL TRATAMIENTO DE SANGRADO UTERINO ANORMAL
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
KR20240037892A
(ko)
|
2021-06-01 |
2024-03-22 |
트리움비라 이뮤놀로직스 유에스에이, 인크. |
클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CN119110809A
(zh)
|
2022-02-23 |
2024-12-10 |
Xencor股份有限公司 |
抗CD28 x抗PSMA抗体
|
|
EP4582106A1
(en)
|
2022-08-29 |
2025-07-09 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate including mutant fc region
|
|
CN120693344A
(zh)
|
2023-02-14 |
2025-09-23 |
德国癌症研究公共权益基金会 |
具有改善的特性的il-15融合蛋白
|
|
EP4527851A1
(en)
|
2023-09-22 |
2025-03-26 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding ltbr and lrrc15
|
|
WO2025147512A1
(en)
*
|
2024-01-02 |
2025-07-10 |
Eli Lilly And Company |
Immunogenicity assessment platform for biotherapeutic proteins
|
|
WO2025185760A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Itabmed Biopharmaceutical (Shanghai) Co., Ltd. |
Multispecific antigen binding proteins and uses thereof
|